Imagen de Portada

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Robert L. Dubin, Steven B. Heymsfield, Eric Ravussin, Frank L. Greenway
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
por: Dario Giugliano, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
por: Giovanni Antonio Silverii, et al.
Publicado: (2024)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
por: Claire H. Parker, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
por: Lucas A. Mavromatis, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
por: Frederick Berro Rivera, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
por: Yu Mi Kang, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies
por: Ronald M. Goldenberg, et al.
Publicado: (2025)

Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
por: Muhammad Aaqib Shamim, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
por: Amanda R. Purcell, et al.
Publicado: (2025)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
por: David C. Klonoff, et al.
Publicado: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
por: Ruoyang Jiao, et al.
Publicado: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
por: Darren Lau, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
por: Andy Bowe, et al.
Publicado: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
por: Karen L. Jones, et al.
Publicado: (2024)

Effectiveness and care continuity in an app‐based, glucagon‐like peptide‐1 receptor agonist‐supported weight‐loss service for women with overweight and obesity in the UK : A real‐world retrospective cohort analysis
por: Louis Talay, et al.
Publicado: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
por: Filip K. Knop, et al.
Publicado: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
por: Yunwen Xu, et al.
Publicado: (2025)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
por: Julio Rosenstock, et al.
Publicado: (2025)

The extent and predictors of off‐label use of GLP ‐1 receptor agonists for weight loss management
por: Zbigniew Siudak, et al.
Publicado: (2025)

A Novel Method to Evaluate Insulin Sensitivity by Combining Continuous Glucose Monitoring and Urinary C‐Peptide Excretion
por: Guillermo Sanchez‐Delgado, et al.
Publicado: (2026)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
por: Irl B. Hirsch, et al.
Publicado: (2024)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
por: Conner E. Johnson, et al.
Publicado: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
por: Fu‐Shun Yen, et al.
Publicado: (2025)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
por: Tae Hyeon Kim, et al.
Publicado: (2024)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
por: Yi‐Chang Chou, et al.
Publicado: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
por: Hans Johnson, et al.
Publicado: (2025)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
por: Jincheng Shen, et al.
Publicado: (2025)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
por: Juliana de Oliveira Costa, et al.
Publicado: (2024)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
por: Stephanie L. Samuels, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue
por: Richard Sotorník, et al.
Publicado: (2025)

Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
por: Wenxuan Li, et al.
Publicado: (2025)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
por: Lucas Duchemin, et al.
Publicado: (2025)

The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism
por: Sarah V. Applebey, et al.
Publicado: (2025)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
por: Jessica Van Laren, et al.
Publicado: (2026)

Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study
por: Donna Shu‐Han Lin, et al.
Publicado: (2024)

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
por: Neeta B. Amin, et al.
Publicado: (2024)

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
por: Yu‐Nan Huang, et al.
Publicado: (2024)